| Subject: | All Remaining Trasylol To Be Removed From Hospital Pharmacies and Warehouses |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Fri, 16 May 2008 - 06:00 am |
| Audience: Cardiovascular Healthcare Professionals, Pharmacists, Hospital Surgical Services Managers Following publication of the Blood Conservation Using Antifibrinolytics: A Randomized Trial in a Cardiac Surgery Population (BART) Study in the May 14, 2008 online issue of The New England Journal of Medicine, Bayer Pharmaceuticals has notified the FDA of their intent to remove all remaining supplies of Trasylol (aprotinin injection) from hospital pharmacies and warehouses. Trasylol... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
|
|
StayAlert!® Virtual Compliance Administrator™ keeps clients informed by email of any changes to Federal regulations, including Joint Commission (TJC, formerly JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG, and many more, and also provides downloadable tools to ensure compliance. StayAlert! is a premium product sold as an annual site-license subscription. With the site license, the client can sign up an unlimited number of users for the email alerts and access to the StayAlert! online regulatory library. StayAlert! is the only comprehensive clinical and regulatory service providing organizations in the healthcare arena with practical applications to meet complex mandated federal requirements. |
|
